A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies

被引：0
|
作者：
Thieblemont, Catherine [1 ]
Stathis, Anastasios [2 ]
Inghirami, Giorgio [3 ]
Karlin, Lionel [4 ]
Morschhauser, Franck [5 ]
Gleeson, Mary [6 ,7 ]
Broussais, Florence [8 ]
Amorim, Sandy [1 ]
Salles, Gilles [4 ]
Facon, Thierry [5 ]
Cunningham, David [6 ,7 ]
Vey, Norbert [9 ]
Bourdel, Fabrice [10 ]
Herait, Patrice [11 ]
Zucca, Emanuele [2 ]
机构：
[1] Hop St Louis, AP HP, Paris, France
[2] Oncol Inst Southern Switzerland, Bellinzona, Switzerland
[3] Weill Cornell Med Coll, New York, NY USA
[4] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France
[5] CHRU Lille, Hop Claude Huriez, F-59037 Lille, France
[6] Royal Marsden Hosp, London SW3 6JJ, England
[7] Royal Marsden Hosp, Sutton, Surrey, England
[8] Inst J Paoli I Calmettes, F-13009 Marseille, France
[9] Inst J Paoli I Calmettes, Oncohematol EToH Dept, F-13009 Marseille, France
[10] Oncol Therapeut Dev, Clichy, France
[11] OncoEthix SA, Lausanne, Switzerland
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia
    Dombret, Herve
    Preudhomme, Claude
    Berthon, Celine
    Raffoux, Emmanuel
    Thomas, Xavier
    Vey, Norbert
    Gomez-Roca, Carlos
    Ethell, Mark
    Yee, Karen
    Bourdel, Fabrice
    Herait, Patrice
    Michallet, Mauricette
    Recher, Christian
    Roumier, Christophe
    Quesnel, Bruno
    [J]. BLOOD, 2014, 124 (21)
  • [2] Development of the BET bromodomain inhibitor OTX015
    Noel, J. Kay
    Iwata, Kazunori
    Ooike, Shinsuke
    Sugahara, Kunio
    Nakamura, Hideo
    Daibata, Masanori
    [J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [3] Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies
    Stathis, A.
    Quesnel, B.
    Amorim, S.
    Thieblemont, C.
    Zucca, E.
    Raffoux, E.
    Dombret, H.
    Peng, Y.
    Palumbo, A.
    Vey, N.
    Thomas, X.
    Michallet, M.
    Gomez-Roca, C.
    Recher, C.
    Karlin, L.
    Yee, K.
    Rezai, K.
    Preudhomme, C.
    Facon, T.
    Herait, R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 196 - 196
  • [4] BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies
    Herait, Patrice E.
    Berthon, Celine
    Thieblemont, Catherine
    Raffoux, Emmanuel
    Magarotto, Valeria
    Stathis, Anastasios
    Thomas, Xavier
    Leleu, Xavier
    Gomez-Roca, Carlos
    Odore, Elodie
    Roumier, Christophe
    Bourdel, Fabrice
    Quesnel, Bruno
    Zucca, Emanuele
    Michallet, Mauricette
    Recher, Christian
    Cvitkovic, Esteban
    Rezai, Keyvan
    Preudhomme, Claude
    Facon, Thierry
    Palumbo, Antonio
    Dombret, Herve
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [5] OTX015, a novel BET-bromodomain (BET-BRD) inhibitor, is a promising anticancer agent for human glioblastoma
    Ouafik, L.
    Berenguer, C.
    Cayol, M.
    Astorgues-Xerri, L.
    Bekradda, M.
    Odore, E.
    Rezai, K.
    Riveiro, M. E.
    Cvitkovic, E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 153 - 153
  • [6] OTX015, a BET-bromodomain (BET-BRD) inhibitor, potentiates the in vitro effects of chemotherapy drugs and targeted agents in human leukemic cell lines
    Astorgues-Xerri, L.
    Canet-Jourdan, C.
    Bekradda, M.
    Cvitkovic, E.
    Herait, P.
    Raymond, E.
    Riveiro, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 183 - 183
  • [7] A phase I pharmacokinetic study of OTX015 for the treatment of patients with hematologic malignancies
    Odore, Elodie
    Rezai, Keyvan
    Riveiro, Eugenia
    Bourdel, Fabrice
    Herait, Patrice
    Cvitkovic, Esteban
    Dombret, Herve
    Lokiec, Francois
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [8] Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies
    Elodie Odore
    François Lokiec
    Esteban Cvitkovic
    Mohamed Bekradda
    Patrice Herait
    Fabrice Bourdel
    Carmen Kahatt
    Emmanuel Raffoux
    Anastasios Stathis
    Catherine Thieblemont
    Bruno Quesnel
    David Cunningham
    Maria E. Riveiro
    Keyvan Rezaï
    [J]. Clinical Pharmacokinetics, 2016, 55 : 397 - 405
  • [9] The BET Bromodomain Inhibitor OTX015 Synergizes with Targeted Agents in Multiple Myeloma
    Gu, Jie
    Song, Sha
    Han, Huiying
    Xu, Hongxia
    Fan, Gao
    Qian, Chen'ao
    Qiu, Yingchun
    Zhou, Wenqi
    Zhuang, Wenzhuo
    Li, Bingzong
    [J]. MOLECULAR PHARMACEUTICS, 2018, 15 (11) : 5387 - 5396
  • [10] OTX015, a novel BET-bromodomain (BET-BRD) inhibitor, displays antitumoral effects in orthotopic and heterotopic models of human glioblastoma
    Astorgues-xerri, Lucile
    Berenger, Caroline
    Cayol, Mylene
    Bekradda, Mohamed
    Odore, Elodie
    Rezai, Keyvan
    Cvitkovic, Esteban
    Riveiro, Maria E.
    Ouafik, L'Houcine
    [J]. CANCER RESEARCH, 2015, 75
12345